Prosecution Insights
Last updated: November 20, 2026

Erin M Bowers, USPTO Patent Examiner

Listed by the USPTO as BOWERS, ERIN M

Tech Center 1600 • Art Units: 1653 1675 1681 1693

This examiner grants 55% of resolved cases

Analysis

BOWERS, ERIN M is a USPTO patent examiner in tech center 1600 and art unit 1653. The profile records 555 resolved cases and an allowance rate of 54.8%. The median time to allowance is 1286 days.

The interview lift is 10.0%, showing a positive but limited association between interviews and allowance outcomes. The listed companies are Promega Corporation, Animal Microbiome Analytics, Inc., and Takeda Pharmaceutical Company Limited. The listed firms are Casimir Jones, S.C., BakerHostetler, and GOODWIN PROCTER LLP. The combination of a mid-range allowance rate and extended pendency supports early evaluation of claim scope and deliberate response sequencing.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

54.8%
Allow Rate
-5.2% vs TC avg
619
Total Applications
+10.0%
Interview Lift
1286
Avg Prosecution Days
Based on 555 resolved cases, 2023–2026

Rejection Statute Breakdown

6.5%
§101 Eligibility
10.1%
§102 Novelty
46.0%
§103 Obviousness
26.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18611181 TWO COMBINED MUTATIONS THAT INTRODUCE THE SECOND ENTRY PATHWAY TO SYNTHESIZED LIGNIN FROM TYROSINE IN PLANTS Non-Final OA Wisconsin Alumni Research Foundation
18930737 METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A Non-Final OA Takeda Pharmaceutical Company Limited
18593314 CONJUGATES AND METHODS OF USE THEREOF Non-Final OA Regents of the University of Minnesota
18883789 METHOD TO INCREASE DRUG SUBSTANCE YIELD Final Rejection PharmaEssentia Corporation
18669411 METABOLIC AND MICROBIAL BIOMARKERS FOR DETECTION OF PANCREATICOBILIARY CANCERS Non-Final OA Northwestern University
18626999 COMPOSITIONS AND METHODS FOR TREATING VASCULAR DISEASE Non-Final OA CASE WESTERN RESERVE UNIVERSITY
18700134 ENDOGLUCANASE WITH IMPROVED STABILITY Non-Final OA Novozymes A/S
17177591 CELL CULTURE METHOD AND CELL CULTURE APPARATUS Final Rejection NIKKISO CO., LTD.
18660851 RNA POLYMERASE VARIANTS Non-Final OA Codexis, Inc.
18701413 GLUCOAMYLASE VARIANTS AND METHODS FOR USE THEREOF Non-Final OA DANISCO US INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Erin M Bowers's allowance rate?

54.8% of resolved applications examined by Erin M Bowers were allowed (555 resolved cases), compared with 23.3% across Art Unit 1653 over the last five years.

Does an interview help with examiner Erin M Bowers?

This examiner's interview lift is +10.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Erin M Bowers take to allow a patent?

Applications allowed by Erin M Bowers took 1,286 days on average from filing to allowance.

Which art unit does examiner Erin M Bowers work in?

Erin M Bowers examines applications in Art Unit 1653 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month